Navigation Links
YM BioSciences reports second quarter 2010 operational and financial results
Date:2/8/2010

MISSISSAUGA, ON, Feb. 8 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX: YM), today reported operational and financial results for the second quarter of fiscal 2010, ended December 31, 2009.

"After rigorous evaluation of numerous global in-licensing opportunities, we proposed to merge Cytopia Limited., a clinical-stage, Melbourne-based drug development company, into YM during the second quarter," said David Allan, Chairman & CEO of YM BioSciences Inc. "Cytopia products are an ideal complement to our current portfolio and this merger provides all shareholders both risk mitigation and a much enhanced prospect for success through the opportunity to link Cytopia's earlier stage products in development to our well-advanced development of nimotuzumab both directly and through our extensive network of international licensees. Subsequent to quarter-end, the merger was completed. The combination of YM and Cytopia is completely aligned with the YM business model to continuously renew our pipeline through additions of promising new drug candidates from the basic research of other organizations."

Highlights for the second quarter of Fiscal 2010:

    -   Signed agreement with Therapure Biopharma, under which it will
        formulate and fill nimotuzumab into sterile vials in its aseptic,
        GMP-certified, and Health Canada-licensed fill suite in Mississauga,
        Canada.

    -   Utilizing YM's IntelliMab(TM) technology, the collaboration between
        the National Research Council of Canada's Biotechnology Research
        Institute (NRC-BRI) and YM resulted in a number of antibodies that
        bind optimally to HER2/neu-over-expressing breast cancer cells while
        minimally binding to HER2 on normal cardiac cells.

    -   Cytopia 
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
5. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
6. YM BioSciences announces result of Cytopia shareholder vote
7. Profectus Biosciences to Present at Key Investor Conference in January 2010
8. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
9. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
10. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
11. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 25, 2014 The report ... Management Market by Product Type & Provider ... Analysis (2014-2019)” defines and segments the market ... revenues. , Browse 152 market data ... and in-depth TOC on “Service Quality Management ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation ... Medtronic, Inc. (NYSE: MDT ) has ... Food and Drug Administration (FDA) for the use ... infusion system (including a newly developed catheter) for ... Injection delivered intravenously to patients with pulmonary arterial ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing ... common stock, and warrants to purchase up to an ... price of $4.00 per share and $.01 per warrant.  ... $5.00, are exercisable immediately, and expire 5 years from ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ... purposes. Under the terms of the ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... 21 Startech,Environmental Corp. (OTC Bulletin Board: ... Company, announced today that the,EnviroSafe Industrial Services ... its original plans for its new recycling-facility ... to install three Plasma Converters Systems,purchased last ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... announced that it has elected to suspend,enrolment in ... its Vascular Wrap,product candidate in patients undergoing surgery ... an imbalance of infections that have,been observed between ...
... A group of German,investors is about to acquire up ... purchasing price of up to EUR 750,000. The acquisition,will be ... subscribed,to by the investors. It will become effective after the ... and after the capital increase will,have been entered in the ...
Cached Biology Technology:Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 2Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 2Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 4Investors Acquire Share in Sangui BioTech GmbH 2
(Date:12/24/2014)...  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames ... own biometrics fused to their smartphones. To assist people ... Hoyos Labs , the company that created 1U and ... offering the app for free. 1U is ...
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... security consultant, Apollo Robbins for the 2015 ... Apollo Robbins will be ... , 2015, demonstrating some of his famous theft techniques ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... announced the addition of the "The ... to their offering. ... provides an overview of the global digital ... to control and monitor piracy by securely ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... it." The saying could apply especially to the brain ... studies have shown that keeping the mind active, exercising ... dementia in Alzheimer,s disease. Now, a new ... Center for Neurologic Diseases in the BWH Department of ...
... 5.8 million Americans suffer from heart failure, a currently ... Medicine,s (TUSM) Center for Translational Medicine have discovered a ... the development of new drugs to treat and possibly ... failure are not very effective," explained lead investigator Walter ...
... A team of European scientists from the University Medical Center ... Cellular Stress Responses in Aging-Associated Diseases (CECAD) at the ... closer to understanding the root cause of age-related dementia. In ... age-related dementia is likely the result of a declining ability ...
Cached Biology News:Use it or lose it 2Temple researchers discover key to heart failure, new therapies on horizon 2Temple researchers discover key to heart failure, new therapies on horizon 3Age-related dementia may begin with neurons' inability to dispose of unwanted proteins 2
The Econo gradient pump rack is a preassembled rack that is used to hold the components of the Econo gradient pump kits....
... 384-well reaction module is used for nucleic ... with an interchangeable, 384-well reaction module (5-20 ... and control and ramp rates that are ... the iCycler base with 384-well reaction module, ...
... is the cycler that revolutionized thermal ... and swappable blocks ensure consistent results, ... rugged machine is more than just ... new features and upgrades as research ...
... Gene Pulser Xcell microbial system, 100 ... used for electroporation of bacterial and ... main unit, PC module for exponential ... sterile cuvettes (5 each of 0.1 ...
Biology Products: